Growing cocrystals by stoichiometric cosublimation

Pharmaceutical Cocrystals: An Overview

In the last few years, a large number of drugs have been discovered with low aqueous solubility. Among these recently discovered drugs, about 60-70% of the compounds are related to the BCS Class II (low solubility/high permeability) and IV (low solubility/ low permeability)[1,2]. Many active pharmaceutical ingredients (APIs) have not been developed in formulations due to low aqueous solubility,...

Improving Lithium Therapeutics by Crystal Engineering of Novel Ionic Cocrystals

Current United States Food and Drug Administration (FDA)-approved lithium salts are plagued with a narrow therapeutic window. Recent attempts to find alternative drugs have identified new chemical entities, but lithium's polypharmacological mechanisms for treating neuropsychiatric disorders are highly debated and are not yet matched. Thus, re-engineering current lithium solid forms in order to ...

Stoichiometric controls of mercury dilution by growth.

Rapid growth could significantly reduce methylmercury (MeHg) concentrations in aquatic organisms by causing a greater than proportional gain in biomass relative to MeHg (somatic growth dilution). We hypothesized that rapid growth from the consumption of high-quality algae, defined by algal nutrient stoichiometry, reduces MeHg concentrations in zooplankton, a major source of MeHg for lake fish. ...

Non-Covalent Derivatives: Cocrystals and Eutectics.

Non-covalent derivatives (NCDs) are formed by incorporating one (or more) coformer molecule(s) into the matrix of a parent molecule via non-covalent forces. These forces can include ionic forces, Van der Waals forces, hydrogen bonding, lipophilic-lipophilic interactions and pi-pi interactions. NCDs, in both cocrystal and eutectic forms, possess properties that are unique to their supramolecular...

Towards more Efficient Screening of Pharmaceutical Cocrystals